Helvellyn in the Lakes?

Yorkshire?

Taletrectinib in ROS1+ Non–Small Cell Lung Cancer: TRUST | Journal of Clinical Oncology ascopubs.org/doi/10.1200/... @n8pennell.bsky.social @ascocancer.bsky.social @oncoalert.bsky.social

@btog.bsky.social @tnewsomdavis.bsky.social @drsanjaypopat.bsky.social

@prof-ali-g.bsky.social
Hi Ali. Any ideas where I can read the latest recommendations/guidance re the ctdna pilot? I think you said there’d be an update this week re its introduction to the routine testing panel and the implications for tissue. Thanks

My takehomes: 1) a large proportion drop Osi 2) Osi delays relapse 3)not bad but couldn’t converted 10% who got a other TKI to Osi 4) the jury is still out re whether it makes people live longer vs Osi on relapse
Fair?

LAURA OS update (LBA4)
👉 Now 31% maturity

❇️ 78% in PBO grp got Osi at PD
❇️ Improved PFS2
❇️ Trend ⬆️ OS HR 0.67, not significant

💭 Confirm activity of Osi
💭 Crossover impacts OS difference
💭 Final maturity due @ 60%
💭 Surprised 1/3 Osi pts = no further treatment at PD

#ELCC25

COCOON: mitigating cutaneous toxicity of Amivantamab

✅ 60% reduction in Gr2+ dermatology AE
✅ Reduction scalp issues+ paronychia
✅ Fewer Ami dose amendments needed

💭 This regimen should be instigated immediately for any patient starting Amivantamab based therapy

#ELCC25

Great ROS1 TKI summary slide from Julian Mazieres

MARIPOSA final OS analysis

❇️ Significant HR 0.75
❇️ 9% 3yr benefit
❇️ Projected mOS 4 years
❇️ Longer control of CNS disease

❗️At the cost of toxicity
❗️No data on duration of toxicity
❗️PROM and QoL data important

More effective than Osimertinib
Most suitable for higher risk pts

#ELCC25

SAVANNAH: Osi+Savolitinib in MET amp/OE EGFR+ post 1L Osi

👉 Protocol evolved over time
👉 34% pts have MET OE/amp

❇️ ORR 56%; mDOR 9.9m
❇️ mPFS 7.5m
❗️32% Gr3+ AE: oedema, N&V, diarr
❗️Dose amendments mainly for Savo

💭 Good that includes MET OE
💭 Expected side effects, not insignificant

Thanks
Apologies!

Thanks Tom
I wasn’t able to see it in the paper but I was wondering what the median length of follow up was following discontinuation of Osi? Or is it just the same as the main adaura paper. Thanks 🙏

Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer - Nature Medicine Exploratory post hoc analysis of molecular residual disease from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer shows that mol...

Honoured to co-first author this important paper with Prof Herbst and the entire team looking at MRD in the ADAURA trial. www.nature.com/articles/s41...

True say. Would want to know that giving Osi earlier makes people live better or longer. My experience with the adjuvants is that I’m always able to start Osi on relapse

@drpeedell.bsky.social please could you disseminate our survey to your colleagues. We are trying to use prediction models to help provide better info to pts when they make their treatment decisions but want to design them so they are useful qualtrics.ucl.ac.uk/jfe/form/SV_...

New Podcast Alert! BTOG Does ... HER2.

Featuring @tnewsomdavis.bsky.social, Dr Emma O'Dowd and Dr Riyaz Shah, listen wherever you get your podcasts (search 'BTOG') or online www.btog.org/btog-podcasts/ .

📊 40% of #lungcancer patients say they didn’t get enough details about their diagnosis.*

📊 22% of UK EGFR+ patients don’t know their mutation type—even though it affects treatment.**

Patients can’t make informed choices without the right info. #LCSM

* LuCE 9th Report
** EGFR+ UK member survey

“We’re talking about people’s lives, not just pathways. If it was your life on the line you wouldn’t settle for 64 days of waiting.” Patient perspective on waits for genomic testing in #lungcancer at #BTOG25

At #BTOG25, our Chair, Debra Montague, addressed: Have we lost the patient voice in genomics? #lungcancer patients must be at the heart of genomic advances. With the focus often on technology & turnaround times, this was a chance to put patient experiences at the centre of the conversation.

#LCSM

‼️ 1 day until #BTOG25 ‼️
Things to look forward to #11

Solange Peters on Tuesday morning: patient selection for neoadj / perioperative SACT.

Previous ESMO President, IASLC board member, ETOP Founder, and all round global superstar.

Fantastic that we have lured her to Belfast

I’m done with the debate! 🥱

Hi Giannis, the link didn’t work for me. Not sure if it’s just me

Biomarker-selected or biomarker-agnostic ADCs for oncogene-addicted #NSCLC❓

💡Just out in @myESMO #CancerTreatmentReviews a comprehensive overview on current landscape, challenges and perspectives

Grateful to work with a global amazing team 🙏

Link to the Review:👇
doi.org/10.1016/j.ctrv…

Check out my hometown of York!

Leaving X

I can’t continue to support X with a clear conscience.

I hope BlueSky replaces it. But I don’t think it will do so quickly unless we drop X, as opposed to us having feet in both camps.

Hoping the community moves over. Unbeatable source of med ed when it’s firing

Every day, 20 people in the UK are told they have #EGFR+ #lungcancer.

No one should have to face that alone. That’s why we’re here—to offer support, raise awareness, and push for earlier diagnosis.

Please support us with a donation if you can 💜 www.egfrpositive.org.uk/donate

#LCSM

Only 1.5% of #lungcancer research focuses on supportive & palliative care. Most people with lung cancer need this, yet it’s almost ignored. This has to change. Debra Montague, ALK+ UK Chair, says: ‘Research must go beyond survival & truly consider QoL.’ Read GLCC’s statement: shorturl.at/tYq1G #LCSM

Comprehensive molecular profiling of squamous non-small cell lung cancer reveals high incidence of actionable genomic alterations among patients with no history of smoking Next-generation sequencing (NGS) to detect actionable genomic driver alterations (AGAs) is critical to appropriate management of non-small cell lung c…

Biomarker testing can help identify actionable mutations in patients with SqNSCLC, especially in those without a history of smoking. Testing is not performed consistently in this setting. #LCSM #lungcancer

www.sciencedirect.com/science/arti...